
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>A Pilot Study of Corticosteroid Treatment for Achalasia‑Variant Esophagogastric Junction Outflow Obstruction  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>A Pilot Study of Corticosteroid Treatment for Achalasia‑Variant Esophagogastric Junction Outflow Obstruction  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastro Hep Advances (pre‑proof) 2026  </li>
<li style="margin-left: 0px;">Authors: Chanakyaram A Reddy, MD; Ashton Ellison, MBchB; Vani J A Konda, MD; Anh D Nguyen, MD; Rhonda F Souza, MD; Stuart J Spechler, MD  </li>
</ul>
<details><summary><strong>1. Background &amp; Rationale  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">EGJOO = impaired LES relaxation with <em>some</em> preserved peristalsis.  </li>
<li style="margin-left: 0px;">Hypothesized subset caused by <strong>type‑2 (allergic) inflammation</strong> → eosinophil/mast cell infiltration → neuronal damage → achalasia‑like dysfunction.  </li>
<li style="margin-left: 0px;">Prednisone (anti‑inflammatory) proposed to test reversibility of this allergic component.  </li>
</ul>
</div></details>
<details><summary><strong>2. Study Design &amp; Population  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective pilot, <strong>10 adult patients</strong> with dysphagia ± non‑cardiac chest pain.  </li>
<li style="margin-left: 0px;">Inclusion: conclusive EGJOO per HRM (CC v4.0), corroborated by esophagram and/or EndoFLIP.  </li>
<li style="margin-left: 0px;">Exclusion: prior foregut surgery, botulinum toxin ≤6 mo, hiatal hernia &gt; 2 cm, mass/stricture, reflux esophagitis LA B‑D, immunosuppressants/opioids.  </li>
<li style="margin-left: 0px;">Intervention: <strong>Prednisone 20 mg PO daily ×14 days</strong>.  </li>
</ul>
</div></details>
<details><summary><strong>3. Baseline Characteristics &amp; Atopic Profile  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Mean age <strong>58.2 y</strong>; gender <strong>5 M / 5 F</strong>.  </li>
<li style="margin-left: 0px;">EGJOO confirmation: FLIP only (4), esophagram only (2), both (4).  </li>
<li style="margin-left: 0px;"><strong>9/10</strong> had atopy (asthma, eczema, food or seasonal allergy).  </li>
<li style="margin-left: 0px;"><strong>2 patients</strong> (#3, #10) diagnosed with EoE (no rings/strictures).  </li>
</ul>
</div></details>
<details><summary><strong>4. Outcome Measures &amp; Data Collection  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Symptom scores: <strong>Eckardt</strong> and <strong>BEDQ</strong>, recorded at baseline &amp; day 14.  </li>
<li style="margin-left: 0px;">Manometry: repeat HRM on day 14 (≤18 mo from baseline).  </li>
<li style="margin-left: 0px;">Integrated Relaxation Pressure (IRP) measured supine &amp; upright.  </li>
</ul>
</div></details>
<details><summary><strong>5. Symptom Score Changes (Pre‑ vs Post‑Prednisone)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Metric</th>
<th>Mean Baseline</th>
<th>Mean Day 14</th>
<th>p‑value</th>
</tr></thead>
<tbody>
<tr>
<td>Eckardt</td>
<td><strong>3.5</strong></td>
<td><strong>3.2</strong></td>
<td>0.315 (NS)</td>
</tr>
<tr>
<td>BEDQ</td>
<td><strong>9.8</strong></td>
<td><strong>8.2</strong></td>
<td>0.385 (NS)</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Individual improvement: Eckardt ↑ in <strong>6/10</strong>, BEDQ ↑ in <strong>8/10</strong>.  </li>
<li style="margin-left: 0px;">Greatest symptomatic gain: patient #10 (atopic + EoE).  </li>
<li style="margin-left: 0px;">Least improvement: patient #6 (no atopy).  </li>
</ul>
</div></details>
<details><summary><strong>6. Manometric Changes (IRP)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Supine IRP:</strong> ↓ from <strong>31.4 ± 8.9</strong> to <strong>22.9 ± 7.7 mmHg</strong>, <em>p</em> = 0.02.  </li>
<li style="margin-left: 0px;"><strong>Upright IRP:</strong> ↓ from <strong>26.1 ± 8.5</strong> to <strong>21.7 ± 8.5 mmHg</strong>, <em>p</em> = 0.03.  </li>
<li style="margin-left: 0px;">Supine IRP decreased in <strong>5 patients</strong>; 4 of these also showed upright IRP reduction.  </li>
<li style="margin-left: 0px;">Normalization achieved in <strong>1 patient</strong> (#2).  </li>
</ul>
</div></details>
<details><summary><strong>7. Safety &amp; Feasibility  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prednisone course well‑tolerated; no serious adverse events reported within the 14‑day window.  </li>
</ul>
<p><em>The above sections constitute the first portion of the mind map, covering background, design, cohort description, and primary outcome data.</em></p>
</div></details>
<details><summary><strong>7. Interpretation of Findings  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Two‑week prednisone <strong>significantly lowered IRP</strong> (both supine &amp; upright).  </li>
<li style="margin-left: 0px;">Symptom scores improved in most individuals despite non‑significant group means.  </li>
<li style="margin-left: 0px;">Suggests <strong>allergic/inflammatory subset</strong> of EGJOO is steroid‑responsive and potentially reversible.  </li>
</ul>
</div></details>
<details><summary><strong>8. Mechanistic Insights Supporting the Allergy Hypothesis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior work: eosinophil infiltrates in esophagectomy/LES biopsies of achalasia patients.  </li>
<li style="margin-left: 0px;">Published data: <strong>mast cell degranulation</strong> in LES muscle (Achalasia).  </li>
<li style="margin-left: 0px;">Th2 cytokine (IL‑4Rα) stimulation → ↑ eotaxin‑3 secretion &amp; smooth‑muscle tension.  </li>
</ul>
</div></details>
<details><summary><strong>9. Relation to Prior Epidemiologic Evidence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Population study: achalasia strongly linked with EoE and other allergic disorders.  </li>
<li style="margin-left: 0px;">Current cohort: <strong>90 %</strong> EGJOO patients had atopy, reinforcing possible allergy‑driven pathogenesis.  </li>
</ul>
</div></details>
<details><summary><strong>10. Comparison With Standard Definitive Therapies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conventional EGJOO/achalasia treatments (pneumatic dilation, Heller myotomy, POEM) = invasive, irreversible LES destruction → symptom relief only, risk GERD, efficacy wanes over time.  </li>
<li style="margin-left: 0px;">Anti‑inflammatory medical therapy offers <strong>potential reversal</strong> before neuronal loss becomes permanent.  </li>
</ul>
</div></details>
<details><summary><strong>11. Study Limitations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No control/placebo arm → cannot exclude spontaneous EGJOO resolution.  </li>
<li style="margin-left: 0px;">Historical spontaneous remission rates (pre‑CCv4.0) = <strong>15 %–74 %</strong> within 6 mo; likely lower with stricter CC v4.0 criteria used here.  </li>
<li style="margin-left: 0px;">Prednisone dose/duration may be insufficient for full reversal; IRP normalized in only one patient.  </li>
<li style="margin-left: 0px;">Inflammatory substrate appears <strong>heterogeneous</strong> across EGJOO cohort.  </li>
</ul>
</div></details>
<details><summary><strong>12. Conclusions &amp; Future Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pilot data <strong>strongly suggest</strong> a steroid‑responsive subset of EGJOO, supporting the type‑2 inflammation hypothesis.  </li>
<li style="margin-left: 0px;">Findings justify larger, controlled trials to:  </li>
<li style="margin-left: 20px;">Confirm causality between allergic inflammation and EGJOO.  </li>
<li style="margin-left: 20px;">Optimize prednisone dosing/duration or explore alternative anti‑inflammatory agents.  </li>
<li style="margin-left: 20px;">Identify biomarkers (e.g., eosinophil count, atopic history) predicting response.  </li>
</ul>
</div></details>
<details><summary><strong>13. Tables &amp; Supplemental Details  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Table 1 – Esophageal Testing Features (Baseline)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pt 1: eosinophils 0; esophagram no liquid retention, tablet retained → DI 0.6, max diameter 5.8 cm.  </li>
<li style="margin-left: 0px;">Pt 2: eosinophils 0; esophagram yes liquid retention, no tablet → DI 2.6, max 14 cm.  </li>
<li style="margin-left: 0px;">Pt 3: peak eos 4/hpf*; esophagram no liquid, yes tablet → DI 1.7, max 9.6 cm.  </li>
<li style="margin-left: 0px;">Pt 4: eos 30/hpf<em></em>; no retention both → DI 0.6, max 6.9 cm.  </li>
<li style="margin-left: 0px;">Pt 5: eos 0; esophagram yes liquid, no tablet → DI 3.5, max 15 cm.  </li>
<li style="margin-left: 0px;">Pt 6: eos 0; FLIP only (no esophagram) → DI 0.8, max 11.5 cm.  </li>
<li style="margin-left: 0px;">Pt 7: eos 0; both esophagram &amp; tablet retained → DI 1.4, max 14.6 cm.  </li>
<li style="margin-left: 0px;">Pt 8: eos 0; both retained → DI 1.4, max 5.1 cm.  </li>
<li style="margin-left: 0px;">Pt 9: eos 0; FLIP only → DI 0.5, max 9.4 cm.  </li>
<li style="margin-left: 0px;">Pt 10: peak eos 15/hpf; FLIP alone positive → DI 2.6, max 13.4 cm.  </li>
</ul>
</div></details>
<details><summary><strong>Table 2 – Clinical &amp; Manometric Outcomes per Patient  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Atopic history</strong> present in 9/10 (all but patient #6).  </li>
<li style="margin-left: 0px;"><strong>Eckardt score:</strong> pre‑Rx mean 3.5 → post‑Rx mean 2.8; individual Δ ranged −2 to +4.  </li>
<li style="margin-left: 0px;"><strong>BEDQ:</strong> pre‑Rx mean 9.8 → post‑Rx mean 7.1; individual Δ up to 20 points (patient #10).  </li>
<li style="margin-left: 0px;"><strong>Supine IRP (mmHg):</strong> baseline mean ≈ 28–31; post‑steroid ↓ to 22–39 in most; only patient #2 normalized (IRP ≤ 15 mmHg).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>13. Implications for Clinical Practice  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Short‑course prednisone may <strong>delay or avoid invasive dilation/myotomy</strong> in allergic EGJOO subset.  </li>
<li style="margin-left: 0px;">Potential to reduce procedure‑related GERD risk and preserve LES function.  </li>
</ul>
<p><em>All factual details from the manuscript have been extracted; administrative text, footers, and reference list omitted.</em></p>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
